Recent Finacing
Recent Raise
OcuTerra is a clinical-stage ophthalmology company developing OTT166, a small-molecule selective integrin inhibitor in at-home topical eye-drop form to reach the retina for diabetic retinopathy and wet AMD.
Focus Areas
Total Raised
Funding round
See the team members at OcuTerra Therapeutics.
